China Investment Roundup: Strategic Overseas Moves Target Product Acquisitions
R&D-based big pharma groups in China with sufficient cash flow are increasing their strategic investments in overseas companies and products with an eye on entry to the global market, while start-ups continue to actively raise new funds from venture capitalists.
You may also be interested in...
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.
Betta Pharmaceuticals hopes strategic initiatives overseas will facilitate its diversification away from a single dominant oncology product. The Chinese firm is facing increasing competition from domestic generics, with revenues and profits under pressure.
Chinese group Fosun’s landmark buyout of Gland Pharma appears less likely to go through in India, at least for now, though some experts claim that the deal has always been a tricky one from the Indian standpoint. Indo-China border tensions are unlikely to make things any easier.